Corcept Therapeutics (CORT) Non Operating Interest Expenses (2011 - 2012)
Corcept Therapeutics (CORT) posted Non Operating Interest Expenses of $1.1 million for Q4 2012, up 83.92% sequentially from $622000.0 in Q3 2012, and up 14200.0% YoY from N/an in Q1 2012.
Corcept Therapeutics (CORT) Non Operating Interest Expenses (2011 - 2012) Analysis & Trends
Corcept Therapeutics has reported Non Operating Interest Expenses for 2 years, with the latest figure at $1.1 million in Q4 2012.
- Quarterly Non Operating Interest Expenses rose 14200.0% year-over-year to $1.1 million in Q4 2012, while the trailing twelve-month figure through Dec 2012 was $1.8 million (changed N/A YoY) and the FY2012 annual result came in at $1.8 million, up 7004.0% from the prior year.
- Non Operating Interest Expenses improved to $1.1 million in Q4 2012 per CORT's latest filing, from $622000.0 in the prior quarter.
- Over five years, Non Operating Interest Expenses peaked at $1.1 million in Q4 2012 and troughed at $1000.0 in Q3 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 1.14 Mn |
| Sep 30, 2012 | 622,000.00 |
| Dec 31, 2011 | 8,000.00 |
| Sep 30, 2011 | 1,000.00 |